NBSE News and Press, NeuBase Therapeutics Inc. From 10/14/22

Workforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Company’s cash runway into Q2 CY2024 The Company plans to maximize shareholder value by focusing R&D resources on advancement of the differentiated gene editing ...

PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of prec...

NeuBase Therapeutics press release ( NASDAQ: NBSE ): Q3 GAAP EPS of -$0.26 beats by $0.04 . As of June 30, 2022, the Company had cash and cash equivalents of approximately $29.8 million, compared with approximately $52.9 million as of September 30, 2021. For furt...

Lead myotonic dystrophy type 1 (DM1) candidate continues to show promising preclinical data, including the pharmacokinetics (PK) and biodistribution data presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting supporting a differentiated whole-body treatme...

NeuBase Therapeutics ( NASDAQ: NBSE ) promotes William (Bill) Mann, Ph.D. to President of the company, effective immediately. Dr. Mann will also continue to serve as the company’s COO. Dr. Mann joined the company as CCO in July 2020. Prior to joining th...

PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of preci...

PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, ...

PITTSBURGH and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precis...

NeuBase Therapeutics press release (NASDAQ:NBSE): Q2 GAAP EPS of -$0.30 misses by $0.06. With continued positive results from in vitro and in vivo preclinical studies, the Company expects to file an IND application for NT-0231.F in the fourth quarter of CY2022. For furth...

Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead myotonic dystrophy type 1 (DM1) candidate; new preclinical data to be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th...